Stock listing

Stockholm:NXTCL NextCell Pharma AB Aktie

Home listing (Stockholm) of NextCell Pharma AB

Follow NextCell Pharma AB into a list and get an email when it puts out news.

Share price · OMXSTO:NXTCL

0.218 SEK -0.011 (-4.6%)

Close on Nov 20, 2026

Past year -73.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.199 – 0.236 SEKNov 20, 2026
Volume
1.44M sharesNov 20, 2026
Market cap
27.49M SEKAt the close on Nov 20, 2026 · price × 126.4M shares outstanding
52-week range
0.199 – 1.784 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
409,237 SEKMedian day 342,455 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
NextCell Pharma AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:NXTCL · Home0.218 SEK-0.011 (-4.6%)1,444,2770.2360.2360.1990.228Close on Nov 20, 2026
Frankfurt:65G€0.0064 EUR+0.0010 (+18.5%)—€0.0064€0.0064€0.0064€0.0054Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:NXTCL · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.218-0.011-4.6%0.2360.2360.1991,444,277
0.228-0.016-6.7%0.2300.2470.22188,823
0.245+0.018+7.9%0.2400.2490.225428,962
0.227-0.013-5.6%0.2600.2600.222343,437
0.240+0.002+0.6%0.2450.2630.239776,936
0.239-0.010-4.0%0.2410.2620.239179,616
0.249-0.033-11.7%0.2550.2630.241190,060
0.282+0.013+5.0%0.2700.2940.263654,236
0.268-0.022-7.6%0.2910.2910.260341,473
0.290+0.004+1.2%0.2850.2940.282261,505
0.287+0.033+13.0%0.2310.3000.231549,538
0.254+0.023+10.2%0.2320.2860.2321,318,377
0.230-0.035-13.2%0.2600.2640.2001,561,388
0.265-0.046-14.8%0.3180.3250.2651,887,788
0.311+0.010+3.2%0.3250.4220.2612,979,360
0.302-0.128-29.7%0.4150.4300.2916,153,623
0.429-0.571-57.1%0.3760.5300.3768,444,404
1.000+0.005+0.5%0.9331.0000.928263,620
0.995+0.035+3.6%0.9600.9950.937213,052
0.960-0.040-4.0%1.0041.0040.95187,051
1.000-0.004-0.4%0.9931.0060.952107,449
1.004+0.048+5.0%0.9851.0060.957263,881
0.956-0.062-6.1%0.9921.0000.936365,113
1.018-0.026-2.5%0.9751.0340.97571,212
1.044+0.062+6.3%0.9811.0440.955506,627
0.982+0.019+2.0%0.9640.9970.939467,298
0.963-0.049-4.8%1.0121.0120.952382,850
1.012+0.012+1.2%1.0121.0240.98594,815
1.000-0.020-2.0%1.0001.0060.972239,584
1.020-0.070-6.4%1.0521.0521.020263,436
1.090+0.050+4.8%1.0421.1041.038271,498
1.0400.0000.0%1.0401.0521.000380,410
1.040-0.058-5.3%1.0541.0600.9801,050,508
1.098-0.020-1.8%1.1181.1181.048100,845
1.118+0.018+1.6%1.0981.1301.046153,546
1.100+0.076+7.4%1.0201.1220.969334,288
1.024+0.006+0.6%1.0001.0420.968455,740
1.018+0.006+0.6%1.0081.0540.996557,732
1.012-0.044-4.2%1.0561.0561.000345,928
1.056+0.010+1.0%1.0441.0561.036116,523
1.046-0.032-3.0%1.0801.0801.030230,669
1.078+0.008+0.7%1.0801.0801.050316,254
1.0700.0000.0%1.0681.0701.038207,704
1.070-0.030-2.7%1.0961.0981.050147,371
1.100+0.054+5.2%1.1121.1121.05066,684
1.046-0.012-1.1%1.0581.0681.016273,950
1.058-0.028-2.6%1.0881.0981.040491,491
1.086-0.064-5.6%1.1481.1481.070106,761
1.150+0.020+1.8%1.1301.1501.090312,619
1.130+0.078+7.4%1.0521.1301.010960,489
1.052-0.018-1.7%1.0721.1001.048357,389
1.070+0.030+2.9%1.0321.0800.997957,910
1.040-0.060-5.5%1.1001.1001.030867,751
1.100+0.012+1.1%1.1381.1381.000526,630
1.088+0.008+0.7%1.0981.1501.06058,461
1.080+0.030+2.9%1.0921.0981.046293,251
1.050-0.050-4.5%1.0801.1501.050360,342
1.100+0.052+5.0%1.0561.1001.042173,729
1.048-0.014-1.3%1.0581.1001.014273,534
1.062-0.054-4.8%1.1881.1881.056312,618
1.116+0.014+1.3%1.1241.1821.060393,543
1.102-0.078-6.6%1.1761.2001.100445,537
1.180+0.080+7.3%1.1001.2380.997571,465
1.100-0.190-14.7%1.3001.3001.074523,993
Ticker
Stockholm:NXTCL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stockholm
Currency
SEK

What changed lately

Latest news

All NextCell Pharma AB news

NextCell Pharma AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 3 in all · newest Jan 21, 2026 · oldest 2025

Where NextCell Pharma AB is listed

ListingExchangeCountryCurrency
Stockholm:NXTCL · Home listing · This pageStockholmSwedenSEK
Frankfurt:65GFrankfurtGermanyEUR

Valuation

EV/sales 0.6× against a median of 32.8×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to May 31, 2026 · price Nov 20, 2026

Enterprise value
6.40M SEK
P/E
Loss
EV/sales
0.6×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
−447.6%
Operating margin
−447.6%
Net margin
−440.8%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
NextCell Pharma AB · OMXSTO:NXTCLUS$2.69MUS$626,140n/a0.6×n/a0.6×−440.8%0.0×n/a
Gelteq Limited · NASDAQ:GELSUS$2.89MUS$6.27Mn/a57.2×n/a0.3×n/a0.4×0.83
Curis, Inc. · NASDAQ:CRISUS$2.85M−US$1.42Mn/an/an/a1.1×n/a0.3×1.85
Fluicell AB · OMXSTO:FLUIUS$2.83MUS$3.03M10.4×1.6×10.7×1.8×14.1%0.1×n/a
Alligator Bioscience AB · OMXSTO:ATORXUS$2.79MUS$1.47Mn/a53.3×n/a1.2×n/a1.2×n/a
Traws Pharma, Inc. · NASDAQ:TRAWUS$2.69MUS$351,448n/an/an/an/an/an/a2.07
Bioxytran, Inc. · OTC:BIXTUS$2.66MUS$2.59Mn/an/an/an/an/an/a-1.20
BioAtla, Inc. · NASDAQ:BCABUS$2.58MUS$2.01Mn/an/an/an/an/an/a-0.34
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
Median of the othersUS$2.68MUS$2.10M10.4×32.8×10.7×0.9×14.1%0.3×0.89

Forecasts

Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
0.80 SEK · Analysts' mean
Revenue, year to Dec 2026
12M · 1 analyst

Team and board

Officers

OfficerRole
Mathias SvahnCEO
Eric GustafssonCFO

Board

DirectorRole
Camilla Myhre SandbergBoard member
Edvard SmithBoard Member
Eva Sjökvist SaersBoard Member
Hans-Peter EkreChariman of the Board

Events

QuarterResultsShare move
Q3 2026Jun 30, 2026−8.9%
Q2 2026Mar 31, 2026−4.8%
Q1 2026Dec 31, 2025−4.0%
Q4 2025Oct 30, 2025 · After close+0.8%
Q3 2025Jul 24, 2025+10.3%
Q2 2025Apr 25, 2025−4.0%
Q1 2025Jan 29, 2025−3.4%
Q1 2022Jan 28, 2022 · Before open+3.6%
Q4 2021Oct 29, 2021−6.4%
Quarter to May 31, 2021Jul 30, 2021+5.5%
All 12 quarters
QuarterResultsShare move
Quarter to Feb 28, 2021Apr 29, 2021−7.5%
Quarter to Nov 30, 2020Jan 29, 2021−2.5%

Open Events

Financings

RaiseDateIn US dollars
Private placement of shares
Announced: SEK 15M · SEK 1 a share · Delphi KB
Dealers: Delphi KB
Buyers: Rustan Panday, through Jehangir AB; Anders Eriksson; Mats Gustafsson; Michaëla Berglund; India von Platen
Use of proceeds: Continued development of drug candidate ProTrans and strengthening working capital
Jan 21, 2026US$1.65M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue10.9M10.7M10.1M5.59M3.91M3.56M1.81M655.4K517.2K809.0K
Cost of revenue46.8M15.2M11.0M27.8M18.4M13.9M15.8M8.83M3.19M5.87M
Gross profit-35.9M-4.56M-884.8K-22.3M-14.5M-10.4M-14.0M-8.17M-2.67M-5.06M
Selling, general and administrative8.50M7.17M10.2M4.85M6.53M5.13M
Operating income-35.9M-43.2M-41.0M-35.0M-24.8M-17.7M-21.5M-14.0M-13.3M-11.4M
Depreciation and amortization2.52M974.7K447.9K457.3K437.0K397.1K348.3K298.7K298.7K298.7K
EBITDA-33.4M-42.2M-40.6M-34.6M-24.4M-17.3M-21.1M-13.7M-13.0M-11.1M
Interest expense2.60K1.36K2.81K13.5K7.57K8.84K7.79K16.2K1.90K1.27K
Income before tax-35.1M-42.0M-39.8M-34.6M-24.6M-17.7M-21.5M-14.0M-13.2M-11.4M
Income tax1.79M1.19M-469.6K7.57K8.84K7.79K30.6K17.5K14.0K
Net income-35.1M-42.0M-39.8M-34.1M-24.6M-17.7M-21.5M-14.0M-13.2M-11.4M
Earnings per share, basic-0.46-0.57-0.58-0.50-0.81-0.80-1.37-0.82-1.67-2.18

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents38.7M46.8M50.0M97.1M139.2M22.0M20.1M3.12M16.6M5.85M
Short-term investments-1.08M-1.13M-1.13M-1.13M
Receivables15.1M13.3M16.5M8.87M7.31M4.07M3.07M1.93M1.26M301.8K
Inventory545.2K545.2K790.7K767.0K11-2.71M-1.93M1-592.2K
Current assets54.4M60.6M67.3M106.8M146.5M26.0M23.2M5.04M17.9M6.44M
Property, plant and equipment9.90M2.90M2.61M2.48M2.43M2.73M3.02M
Total assets76.7M81.3M88.8M124.7M155.6M29.8M26.7M8.51M21.6M9.47M
Accounts payable2.69M6.16M891.6K1.92M1.28M477.6K1.42M651.8K878.1K552.7K
Current liabilities5.43M9.87M10.1M6.93M3.96M2.17M2.82M2.71M1.86M2.00M
Total liabilities10.3M13.7M13.1M9.12M5.53M3.56M3.76M3.47M2.55M2.70M
Shareholders' equity66.4M67.6M75.7M115.5M150.1M26.2M23.0M5.04M19.1M6.76M
Shares outstanding76.4M73.1M68.8M68.8M30.4M22.2M15.7M17.0M7.93M5.23M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-38.9M-37.8M-43.8M-33.3M-25.6M-19.0M-22.1M-13.5M-14.8M-11.1M
Capital spending-4.18M-82.9K-4.10M-7.59M-725.9K-787.1K-396.5K-396.5K-396.5K-142.1K
Free cash flow-43.0M-37.9M-47.9M-40.9M-26.3M-19.7M-22.5M-13.5M-14.8M-11.3M
Cash from investing-4.24M-83.5K-4.10M-9.37M-5.84M-590.0K-401.5K-401.5K-401.5K-142.1K
Cash from financing35.0M34.6M835.7K608.2K148.6M21.4M39.5M64.7K25.6M8.39M
Change in cash-8.07M-3.23M-47.1M-42.1M117.2M1.83M17.0M-13.5M10.8M-2.85M

Open Financials

Cap table

Built by 6ix from NextCell Pharma AB’s releases · as of Jan 21, 2026

Common shares
126,392,959
Fully diluted
126,392,959

Fully diluted

LineShares
Common shares126,392,959

Share count over time

CountShares
Nov 22, 2026126,392,959

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Camilla Myhre SandbergBoard member · Since at least Nov 5, 2026
Edvard SmithBoard Member · Since at least Nov 5, 2026
Eric GustafssonCFO · Since at least Nov 20, 2025
Eva Sjökvist SaersBoard Member · Since at least Nov 5, 2026
Hans-Peter EkreChariman of the Board · Since at least Nov 5, 2026
Mathias SvahnCEO · Since at least Nov 20, 2025

Open People

Log in to ask 6ix AI your own questions about NextCell Pharma AB.